The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

UPDATE 1-China's Clover in research venture with GSK on coronavirus vaccine candidate

Mon, 24th Feb 2020 08:51

(Adds details on GSK, vaccine effort)

Feb 24 (Reuters) - China's Clover Biopharmaceuticals said https://www.businesswire.com/news/home/20200224005319/en
on Monday it will work with Britain's GlaxoSmithKline
on a research tie-up that will develop the Chinese company's
protein-based coronavirus vaccine candidate "COVID-19 S-Trimer".

Fears of a coronavirus pandemic grew on Monday after sharp
rises in new cases reported in Iran, Italy and South Korea but
China relaxed restrictions on movements in several places
including Beijing as its rates of new infections eased.

Clover, a clinical-stage biotechnology company focused on
developing novel biologic therapies, said GSK will
provide it with its pandemic adjuvant system for further
evaluation of the vaccine candidate in preclinical studies.

GSK is already working with developers by providing a
technology that could make their vaccines more potent. The
drugmaker is collaborating with the Coalition for Epidemic
Preparedness Innovations to contribute towards the effort of
developing a vaccine for the coronavirus outbreak.

The use of adjuvants or agents allow for production of more
vaccine doses and hence would increase availability to more
people.

"The use of an adjuvant is of particular importance in a
pandemic situation since it may reduce the amount of vaccine
protein required per dose," Thomas Breuer, Chief Medical Officer
of GSK Vaccines, said.

Drugmakers racing to find a vaccine or effective treatment
for the deadly new coronavirus in China have, however, cautioned
that they have a long way to go, countering reports of supposed
breakthroughs.

At least a dozen drugmakers are working on vaccines or
antivirals and other treatments to help those infected with the
fast-spreading contagion.

GSK's Breuer said earlier this month that it will take at
least 12 to 18 months to find a vaccine or effective treatment.
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Maju
Samuel, Bernard Orr)

Related Shares

More News

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

17 Jun 21 09:48

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

17 Jun 21 09:36

Wednesday broker round-up

(Sharecast News) - Pets At Home: Berenberg reiterates buy with a target price of 540p.

16 Jun 21 12:50

Tuesday broker round-up

(Sharecast News) - Page Group: Morgan Stanley downgrades to underweight with a target price of 545p.

15 Jun 21 13:39

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.